Message from the directors
Bonac was established to act as a bridge to provide various solutions for the advancement and development of medical care involving nucleic acids across the world through nucleic acid chemistry, including the discovery of pharmaceutical products and development of diagnostic drugs.
We have conducted research from unique perspectives to overcome the issues associated with the development of nucleic acid medicines, and as a result of this we discovered a new nucleic acid molecule “Bonac Nucleic Acid,” which led to the establishment of solid fundamental technologies. These fundamental technologies were applied for a patent in various countries as innovative technology, and have been registered for patent in Japan, US, and Europe.
Highly active research is being conducted in Japan in the area of nucleic acid chemistry, and the research on seeds related to nucleic acid medicines is said to be of the highest standard globally. However, in the current situation, Japan is falling significantly behind in the industrialization of nucleic acid medicines compared to other countries.
Bonac uses the fundamental technology established by the development of “Bonac Nucleic Acid” as the nucleus to realize industrialization in the area of nucleic acid medicine.
There are three specific targets for the achievement of this goal, which are:
“Development of nucleic acid ingredients and molecules which are able to withstand the development of nucleic acid medicine”
“Planning and implementation of strategies for intellectual properties related to the nucleic acid ingredients and molecules developed”
“Promoting the development of nucleic acid medicines”
We combine the strengths of the company as one and create nucleic acid medicines to realize the provision of pharmaceuticals and medical care with even higher quality and value, thereby contributing to the health of people around the world and the future of medical care.
We believe that it is important for executives and staff to join forces and accumulate efforts daily in order to improve the corporate value, and for this reason we promote management based on the idea that all members of executives and staff in the company are important assets to the company.
We aim to provide you with innovative nucleic acid medicines that did not exist previously as soon as possible, for the patients who are fighting disorders at this moment, as well as to meet the needs of the medical setting.
Tadaaki Ohgi, Chairman of the Board
Hirotake Hayashi, Chief Executive Officer